Abstract
A 3-year-old boy with Hodgkin lymphoma relapsed only 2 months after completion of first-line therapy. He received reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation (RIC allo-HSCT), but relapsed again. To treat the second relapse, donor lymphocyte infusions were performed four times. He showed no evidence of disease and his quality of life was maintained for 500 days after stem cell transplant. However, his condition worsened and he died 3 years and 3 months after onset. In high-risk patients fully intolerant to myeloablative regimens, RIC allo-HSCT followed by subsequent donor lymphocyte infusions must be considered an effective therapeutic approach.
This is a preview of subscription content, log in via an institution to check access.
References
Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transpl. 2006;12:172–83.
Peggs KS, Sureda A, Qian W, et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol. 2007;139:70–80.
Eichenauer DA, Engert A. Advances in the treatment of Hodgkin lymphoma. Int J Hematol. 2012;96:535–43.
Porter DL, Stadtmauer EA, Lazarus HM. ‘GVHD’: graft-versus-host disease or graft-versus-Hodgkin’s disease? An old acronym with new meaning. Bone Marrow Transpl. 2003;31:739–46.
Paillard C, Salmon A, Curtillet C, et al. Evidence of a clinical response at one yr after reduced-intensity allogeneic hematopoietic stem cell transplantation in heavily pretreated adolescents with aggressive refractory Hodgkin’s lymphoma. Pediatr Transpl. 2010;14:109–14.
Huff CA, Fuchs EJ, Smith BD, et al. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transpl. 2006;12:414–21.
Daw S, Wynn R, Wallace H. Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents. Br J Haematol. 2011;152:249–60.
Claviez A, Sureda A, Schmitz N. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin’s lymphoma. Bone Marrow Transpl. 2008;42:S16–24.
Corradini P, Sarina B, Farina L. Allogeneic transplantation for Hodgkin’s lymphoma. Br J Haematol. 2011;152:261–72.
Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:455–62.
Thomson KJ, Peggs KS, Smith P, et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin’s lymphoma following autologous stem cell transplantation. Bone Marrow Transpl. 2008;41:765–70.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
oba, U., Koga, Y., Suminoe, A. et al. Donor lymphocyte infusion is an effective therapy for relapsed Hodgkin lymphoma after reduced-intensity allogeneic hematopoietic stem cell transplantation. Int J Hematol 100, 511–513 (2014). https://doi.org/10.1007/s12185-014-1654-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-014-1654-3